Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AXL | P30530 | 7/20 | 0.48 |
| ▸ | NR1H2 | P55055 | 3/20 | 0.41 |
| ▸ | CKS1B | P61024 | 1/20 | 0.41 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.41 |
| ▸ | SLC40A1 | Q9NP59 | 1/20 | 0.40 |
| ▸ | ACLY | P53396 | 3/20 | 0.40 |
| ▸ | NR1H3 | Q13133 | 3/20 | 0.39 |
| ▸ | PTGES2 | Q9H7Z7 | 3/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1592031 | 0.94 | AXL (0.47) | AXLNR1H2CKS1BSKP2SLC40A1 | |
| SCHEMBL1591670 | 0.92 | AXL (0.49) | AXLNR1H2SLC40A1NR1H3PTGES2 | |
| SCHEMBL1591247 | 0.91 | AXL (0.52) | AXLNR1H2CKS1BSKP2SLC40A1 | |
| SCHEMBL1592082 | 0.87 | AXL (0.61) | AXLSLC40A1NR1H3 | |
| SCHEMBL1590952 | 0.86 | AXL (0.46) | AXLGAAKMT2A | |
| SCHEMBL1591711 | 0.86 | AXL (0.46) | AXLNR1H2ACLYNR1H3GAA | |
| SCHEMBL1591907 | 0.85 | AXL (0.55) | AXLSLC40A1ACLYNR1H3 | |
| SCHEMBL1591257 | 0.83 | AXL (0.55) | AXLSLC40A1KMT2A | |
| SCHEMBL1592100 | 0.83 | AXL (0.53) | AXLNR1H3 | |
| SCHEMBL1591135 | 0.82 | AXL (0.50) | AXLNR1H3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110092503-A1 | QUINOLINE DERIVATIVES AS AXL KINASE INHIBITORS | MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E.V. (DE) | 2011-04-21 | — | — | US | claimed |
| US-9206130-B2 | Quinoline derivatives as AXL kinase inhibitors | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2015-12-08 | — | — | US | disclosed |
| US-9206130-B2 | Quinoline derivatives as AXL kinase inhibitors | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2015-12-08 | — | — | US | disclosed |
| US-20110092503-A1 | QUINOLINE DERIVATIVES AS AXL KINASE INHIBITORS | MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E.V. (DE) | 2011-04-21 | — | — | US | disclosed |
| US-20110092503-A1 | QUINOLINE DERIVATIVES AS AXL KINASE INHIBITORS | MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E.V. (DE) | 2011-04-21 | — | — | US | disclosed |
| US-20110092503-A1 | QUINOLINE DERIVATIVES AS AXL KINASE INHIBITORS | MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E.V. (DE) | 2011-04-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110092503-A1 | QUINOLINE DERIVATIVES AS AXL KINASE INHIBITORS | AXL, FLT3, TYRO3 | AXL 1/4885NR1H2 1407/4885CKS1B 215/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.